Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition

NCT02291367 | Completed Phase 1 DMC

• 1 other identifier: BA085908801
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

This study were to compare the relative bioavailability of Duloxetine HCl delayed release capsule 60 mg with that of 'CYMBALTA®' delayed release capsule 60 mg (Duloxetine HCl delayed release capsule 60 mg) in healthy, adult, human subjects under fasting conditions and to monitor safety of subjects

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Area under curve (AUC)

  1.0, 2.0,3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 11.0, 12.0, 24.0, 36.0, 48.0,60.0 and 72.0 hours post dose

Study Arms (2)

Duloxetine Delayed-Release Capsules, 60 mg

EXPERIMENTAL

Drug: Duloxetine

Cymbalta

ACTIVE COMPARATOR

Cymbalta® 60 mg capsule of Eli Lilly and Company

Drug: Cymbalta®

Interventions

Duloxetine DRUG

Duloxetine Delayed-Release Capsules 60 mg

Also known as: Cymbalta

Duloxetine Delayed-Release Capsules, 60 mg

Cymbalta® DRUG

60 mg capsule of Eli Lilly and Company

Cymbalta

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Be healthy human between 18 and 45 years
• Screened within 21 days prior to administration of first dose of study drug
• Having a BMI between 18.5 and 24.9 weight in kg/ height2 in meter
• Be able to communicate effectively with study personnel
• Be able to give Written informed consent to participate in the study If subject is a female volunteer and
• is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
• is postmenopausal for at least 1 year.
• is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).

You may not qualify if:

• History of allergic responses to Duloxetine or other related drugs.
• Have significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG \& X-ray recordings.
• Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
• History or presence of bronchial asthma.
• Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
• History of drug dependence, recent history of alcoholism or of moderate alcohol use.
• Smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who can not refrain from smoking during study period.
• History of difficulty with donating blood or difficulty in accessibility of veins. Donation of blood (I unit: 350 mL/450 mL) within 90 days prior to receiving the first dose of study medication.
• A positive hepatitis screen (includes subtypes A, B, C \& E)
• A positive test result for HIV antibody and/or syphilis (RPR/VDRL).
• The receipt of an investigational product, or participation in a drug research study within a period of 90 days prior to the frst dose of study medication administration.
• Female volunteers demonstrating a positive pregnancy screen
• Female volunteers who are currently breast-feeding
• Female volunteers not willing to use contraception during the study

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead

Study Sites (1)

BA Research India Ltd

Ahmedabad, Gujarat, 380 054, India

Location

MeSH Terms

Interventions

Duloxetine Hydrochloride

Intervention Hierarchy (Ancestors)

Thiophenes; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Mayur Soni, MBBS

  BA Research India Ltd

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 11, 2014
• First Posted: November 14, 2014
• Study Start: May 1, 2008
• Primary Completion: May 1, 2008
• Study Completion: May 1, 2008
• Last Updated: November 14, 2014

Record last verified: 2008-07

Locations

IN (1)